| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |




From the Structural Cell Biology Unit,* Department of Medical Anatomy, Section A, the Panum Institute, the Department of Pathology,
Rigshospitalet, the Institute of Medical Biochemistry and Genetics,
the Panum Institute, the Zoophysiological Laboratory,
the August Krogh Institute, Copenhagen, Denmark; and the Ernest Orlando Lawrence Berkeley Laboratory,¶ Life Sciences Division, Berkeley, California
| Abstract |
|---|
|
|
|---|
-smooth muscle actin-positive stromal reaction. To study the lineage, and the nature of the cells in the stromal reaction, we derived a novel cell line, HBFL-1, from the explanted biopsy. HBFL-1 cells are immortal and exhibit a shared non-random X-chromosome inactivation pattern with the epithelial tumor of origin. Yet they closely resemble normal, finite-life-span fibroblasts by morphology, lack of tumor formation in nude mice, marker expression profile, protein pattern using two-dimensional gel electrophoresis and the ability to undergo myofibroblast conversion. HBFL-1 interacts reciprocally with tumor cells in collagen gel to induce activation of MMP2, leading to tumor-like behavior of epithelial colonies. In vivo, HBFL-1 cells resembled normal-derived myofibroblasts and conferred a significant 3.5- to 7-fold increase in MCF-7 tumor size in nude mice. However, that they were indeed not normal fibroblasts was revealed by residual keratin expression and formation of epithelial microfoci in a reconstituted basement membrane and in nude mice. We conclude that breast cancer can generate its own nonmalignant stroma and that one function for this is that of a reciprocal interaction with epithelial tumor cells to facilitate tumor growth.
-smooth muscle actin (
-sm actin) induced and they were non-tumorigenic and reciprocally interactive with epithelial tumor cells in collagen gels and in co-inoculates in nude mice. The self-supply of a nonmalignant stroma that facilitates epithelial tumor growth may in part explain the poor prognosis of some breast cancers that show evidence of EMT. | Materials and Methods |
|---|
|
|
|---|
A breast carcinoma was obtained from the Department of Pathology, Rigshospitalet, from residual material. Histologically, the carcinoma was classified as metaplastic. Phenotypically normal tissue from the same patient was dissected from the mastectomy specimen at a site remote from the cancer. The use of such tissue material has been reviewed by the Regional Scientific-Ethical Committees for Copenhagen and Frederiksberg, Denmark and found consistent with Laws no. 503 of 24th June 1992 and no. 499 of 12th June 1996 (KF) 01161/98. The tissue was collected in culture medium (Dulbeccos modified Eagles medium-Hams F12 (DME-F12) supplemented with 20% fetal calf serum (FCS) and processed as previously described.12 For zymography and TGF-ß experiments, a subline (S2) was cultured in chemically defined medium alone (DME-F12). Clonal cultures for studies of multipotency were performed as previously described13 using a subline (W2331) propagated in the presence of 20% FCS. One clonal subline (S4) was generated by limited dilution and isolation of the clonal cell islet by trypsinization under the microscope within a Perspex ring. The cells were split 1:3 once a week, and have been kept in culture for more than 3 years. They are referred to as human breast fibroblast-like-1 cells (HBFL-1).
Other Cell Lines
Purified primary breast fibroblasts were obtained from reduction mammoplasties or from within a normal appearing area of the HBFL-1 biopsy and cultured in the presence of 20% FCS as previously described to obtain experimentally generated myofibroblasts.12
In some instances the cells were immortalized by transduction with a retroviral construct containing the HPV16 E6 and E7 oncogenes (ATCC) or the catalytic subunit of human telomerase hTERT (14
kindly provided by Dr. Judy Campisi, Lawrence Berkeley National Laboratory). For zymography MCF-7 subline 9 cells, kindly provided by Dr. Per Briand,15
were cultured alone or recombined with HBFL-1 or primary breast fibroblasts in DME-F12. HMT3909S1, HMT3522T4-2 and MCF-7 (5% FCS) cells were cultured as previously described.16-18
For induction of
-sm actin 20% fetal calf serum and/or 100 pg/ml TGF-ß1 (Sigma Chemical Co., T-1654, Sigma-Aldrich, Vallensbeck Strand, Denmark) were added to the media for 6 days (up to 17 days for the MCF-7 cells), and the medium was changed every second day. For zymography (see below) HT-1080 cells were cultured in RPMI supplemented with 10% FCS. As controls for characterization of HBFL-1 cells we also used primary luminal epithelial cells and myoepithelial cells cultured as previously described.19
Immunocytochemistry
The original routine formalin-fixed, paraffin-embedded biopsy was sectioned at a 4 µm thickness and stained for
-sm actin (1A4, Sigma), Vimentin (3B4 Boehringer Mannheim Roche, Hvidovre, Denmark), keratin CK7 (OV-TM, DAKO, Glostrup, Denmark) and Wide range keratins (MNF116, DAKO). The antibodies were visualized by streptavidin-biotin (DAKO 5004).
Cell cultures were stained for immunofluorescence as previously described, and double stainings were performed with isotype specific antibodies.20,21
Immunoperoxidase cytochemistry and quantification of immunostainings were performed as previously described.13,19
The following primary antibodies were used: cytokeratin K14 (C-8791, Sigma), EDA-fibronectin (DH1; Locus Genex, Helsinki, Finland), K17 (M-7046, DAKO), Ki-67 (M722, DAKO), P53 (M7001, DAKO), uPA (kindly provided by Dr. Boye Schnack Nielsen, The Finsen Laboratory, Copenhagen, Denmark), K18 (F3006, Monosan, Am Uden, The Netherlands), K19 (M772, DAKO), pankeratins (which stained also myoepithelial cells; LP34, M717, DAKO,22
); vimentin (6400-301, Labsystems, Helsinki, Finland), BG3C8 (kindly provided by Dr. J. E. Celis; the Danish Cancer Society, Denmark23
), ß4-integrin (MAB 1964, Chemicon International Inc., Temecula, CA),
1-integrin (VLA-1, T Cell Diagnostics, Cambridge, MA),
V-integrin (MAB 1953, Chemicon), P- and E-Cadherin (NCC-CAD-299 and HECD-1; Kindly provided by Dr. Atsushi Ochiai, Tokyo, Japan), desmoplakin I+II (clone DP1&22.15; Boehringer Mannheim, GmbH), maspin (M45620, Transduction Laboratories, Lexington), connexin 43 (03-6900, Zymed Laboratories Inc., South San Francisco, CA), smooth muscle myosin heavy chain (kindly provided by Dr. V. E. Koteliansky21
), laminin (M638, DAKO), sialomucin (MAM6, clone 115D8, kindly provided by Dr. J. Hilgers, The Netherlands), estrogen receptor (M7047, DAKO), Thy-1 (ASO-2, Dianova, Hamburg, Germany;24
), 1B10 (MC-48, Sigma),
-sm actin, (A-2547, Sigma), type IV collagen (PHM12, Silenus, Victoria, Australia), HGF-receptor (c-met; 05-237, Upstate Biotechnology, Lake Placid, NY), and CALLA (J5, Coulter Immunology, Miami, FL). Immunofluorescence was visualized using a Zeiss LSM 510 laser scanning microscope (Carl Zeiss, Jena, GmbH).
Karyotyping
Chromosome preparations were made from exponentially growing cultures treated for 1.5 hours with colcemid (Gibco BRL, Invitrogen, Tåstrúp, Denmark) at final concentrations of 0.1 µg/ml. Cells were further harvested, centrifuged, and treated with hypotonic solution as previously described.25 The cell pellet was fixed in methanol:glacial acetic acid (3:1) dropped on cold slides and stained for Giemsa bands. Chromosome counts were done on well-spread metaphases.
Telomeric Repeat Amplification Protocol (TRAP) Assay
Experimentally generated myofibroblasts and HBFL-1 cells were grown to 70 to 80% confluence, trypsinized and counted. Cells (106) were washed twice in PBS, pelleted, and stored at -80°C. The telomerase activity was determined with the TRAP assay26 using the TRAPeze Telomerase Detection Kit (Intergen, Oxford, UK, purchased from AHdiagnostics, Aarhus, Denmark) according to the manufacturers instructions.
Human Androgen Receptor (HUMARA) Clonality Assay
Laser pressure catapulting was performed as described using 500 to 1000 cells for lysis.27 To isolate DNA, the lysate was phenol-chloroform extracted with 200 µl of 25:24:1 phenol:chloroform:isoamyl alcohol (Sigma, P2069), followed by ethanol precipitation in the presence of glycogen (Roche, Hvidovre, Denmark). DNA extraction from HBFL-1 and tumor and normal breast specimens was performed with the Qiagen, QIAamp Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturers instructions.
The HUMARA clonality assay was performed in the original formulation with a few modifications.28 The extracted DNA was divided in two, and incubated over night at 37°C in a final volume of 20 µl with or without 10 U HpaII (Roche) according to the manufacturers recommendations. It was heat inactivated for 10 minutes at 95°C, and 5 µl was PCR-amplified in a 15 µl volume. HPLC-purified primers were as follows: sense: 5'tcc aga atc tgt tcc aga gcg tgc-3'; and FAM-labeled antisense: 5'FAM-gct gtg aag gtt gct gtt cct cat-3'28 (Applied Biosystems). The cycling conditions were 15 minutes at 95°C, followed by 28 to 32 cycles of 95°C (1 minute), 60°C (1 minute), 72°C (1 minute), and extension (7 minutes). The PCR product (3 µl), together with a 350 TAMRA internal size marker for assessment of allelic sizes, was electrophoresed on an ABI PRISM 310 Genetic Analyzer using the Performance Optimized Polymer-4 (Applied Biosystems, Perkin Elmer). Fluorescent peaks were identified using the Genescan software version 3.1 (Applied Biosystems). Clonality ratios were calculated according to Willman et al,29 and a clonal ratio of less than 0.5 was considered indicative of a clonal composition.30,31
Two-Dimensional Gel Electrophoresis
Cells were treated and submitted to two-dimensional gel electrophoresis as previously described.32
Tumorigenic Potential
HBFL-1 cells between passages 2138 were cultured in T-75 flasks for transplantation. Confluent cultures were trypsinized and resuspended in DME-F12. Approximately 107 cells were inoculated adjacent to the fourth mammary gland of athymic female mice. A total of six mice were inoculated and were observed weekly for tumor formation for more than 3 months. In another series of experiments, HBFL-1 cells were co-inoculated with MCF-7 cells (n = 6 mice). Finally, two series of experiments (a total of 18 mice) were conducted to see the possible effect of implantation of cells in laminin-rich gels. The gels consisted of 300 µl of 20% reconstituted basement membrane (Matrigel, Engelbreth-Holm-Swarm matrix, Collaborative Biomedical Products, purchased from Becton Dickinson, Catalog no. 40230A, lot no. 913156) and 80% Vitrogen (Collagen Corporation, Fremont, CA33 ) containing either HBFL-1 cells, cloned HBFL-1 cells (S4), MCF-7 cells, HBFL-1+MCF-7 cells, primary experimentally generated myofibroblasts or primary experimentally generated myofibroblasts from reduction mammoplasties+MCF-7 cells. Each cell type was added to the gel at a concentration of 106 cells. The gels were implanted in triplicate subcutaneously in the right flank adjacent to the fourth mammary gland following 24 hours in culture. The tumors were observed weekly for 1 month and the final size determined by weight. Significance was assessed by Students t-test.
Response to Cytokines
HBFL-1 cells cultured in DME-F12 without serum were exposed to 100 pg/ml TGF-ß1 (T-1654, Sigma) or vehicle (4 mmol/L HCl with 1 mg/ml BSA), and the level of induction of
-sm actin was analyzed after 6 days by immunoperoxidase cytochemistry.34
The effect of FGF-2 (basic fibroblast growth factor, bFGF, Pepro Tech EC Ltd., London, UK) on this induction was tested by concurrent exposure to 1 ng/ml FGF-2. TGF-ß1 experiments are described above (see other cell lines and biopsies used).
Reconstituted Basement Membrane Assay
HBFL-1 cells or experimentally generated myofibroblasts (105) were embedded as single cells in 300 µl reconstituted basement membrane (Matrigel) and allowed to gel for 30 minutes. at 37°C. The cultures were kept for 2 to 3 weeks before the gels were frozen and stored. Some gels were sectioned and stained with immunoperoxidase for laminin, keratin K19, ß4-integrin, and type IV collagen.
Tumor Environment Assay
Collagen gels (Cellon S. A., Strassen, Luxemburg) were prepared at a concentration of 2 mg/ml at a volume of 2 ml per well in 6-well dishes (Nunc) as previously described.17,21 2.2 x 105 HBFL-1 cells or primary breast fibroblasts and 5 x 105 MCF-7S9 cells, either separately or together. For substrate gels (MMP2, see below) medium was collected and frozen for later use. At the end of the experiments, gels were snap frozen in -80°C N-hexane, mounted, and sectioned for histological examination.17
Zymography
Zymography was performed using 7.5% SDS-PAGE (BioRad) containing 0.1% gelatin as substrate for gelatinase activity. The serum-free supernatants from the tumor environment assay were concentrated using Centriplus concentrator, 10 kd cut-off (Amicon, Bedford, MA), and the protein concentration of each sample was determined spectrometrically (Beckman), adjusted to 1000 µg/ml. MMP bands were developed by incubation for 24 hours in 50 mmol/L Tris-HCl, 0.2 mol/L NaC1, 5 mmol/L CaCl2, pH 7.4.
Reverse Transcription-PCR
Total RNA from HBFL-1 cells cultured in DME-F12 with or without 1 ng/ml FGF-2 (see above), was isolated with the TRIZOL reagent (Life Technologies, Roskilde, Denmark) according to the manufacturers instructions. RNA (2 µg) was DNase-treated (DNase I Amp Grade, Gibco BRL) and served as a template for first strand cDNA synthesis with an oligo dT primer (Superscript Preamplification System, Gibco BRL). One µl of cDNA was subsequently PCR-amplified using Expand High Fidelity PCR System (Roche, Hvidovre, Denmark) and synthetic oligonucleotide primers for urokinase plasminogen activator (uPA) 5'-AAAATGCTGTGTGCTGCTGAC-3' and 5'-CCCTGCCCTGAAGTCGTTAGTG-3', product size 704 bp,35 stromelysin-3 (STR-3) 5'-CCATGGCAGTTGGTGCAGGAGCAG and 5'-CTGCAGTCATCTGGGCTGAGACTC, product size 401 bp, and ß-actin 5'-CACTGGCATCGTGATGGACTC-3' and 5'-TCTGCATCCTGTCGGCAATGC-3', product size 500 bp (TAG Copenhagen, Copenhagen, Denmark). PCR conditions for uPA were 94°C, 58°C, and 72°C for 1 minute each, 26 cycles for uPA and 94°C, 64°C and for ß-actin, 72°C for 1 minute each, 18 cycles. Amplifications without reverse transcription were included as controls.
| Results |
|---|
|
|
|---|
A new cell line, HBFL-1, was established permanently in culture from a breast carcinoma. Initial morphological characterization showed that under serum-free conditions, the cells resembled non-activated primary fibroblasts (Figure 1A, a and b)
.17
In the presence of serum, they took up an appearance very similar to that of activated primary fibroblasts (Figure 1A, c and d)
.34
Two-dimensional gel electrophoresis of total proteins and staining for a panel of breast cell markers revealed a protein fingerprint which clearly resembled that of resident fibroblasts, the most common precursor of myofibroblasts (Figure 1A, e and f
, and Table 1
).21
For lists of markers see also Refs. 21, 32, 36, 37
.
|
|
-sm actin positive cells was 14 ± 8%. TGF-ß1 induced this level to 45 ± 8%, and FGF-2 reduced it even below the baseline to 8 ± 2%. Second, others have produced evidence that the addition of FGF-2 to the typical peritumoral myofibroblast induces uPA.38
In this respect also the cell line conformed with the definition of myofibroblasts both at the mRNA (Figure 1B)
Finally, as another evidence of the typical myofibroblast behavior, we analyzed the interaction of HBFL-1 cells with cancer cells in a tumor environment assay.17,21,40
Cross-talk between the two cell types was clearly taking place, because tumor cells (MCF-7) could induce both inactive and active isoforms of MMP2 in HBFL-1 cells (Figure 1C)
. The targeting of MMP2 activity to HBFL-1 cells was confirmed immunocytochemically (Figure 1D, a and b)
. Similarly, peritumoral myofibroblasts expressed EDA-fibronectin and
-sm actin (Figure 1D, cf
). Reciprocally, the fibroblasts allowed tumor cells to spread in the collagen gel (Figure 1C)
and induced strong and widespread staining of Ki-67 in the tumor cells (Figure 1D, g and h)
.
To ascertain a functional significance of HBFL-1 also in vivo, inoculates were made subcutaneously in the region of the fourth mammary gland of nude mice in the presence of Matrigel33
with or without MCF-7 cells. Both HBFL-1 and experimentally generated myofibroblasts significantly augmented tumor formation by MCF-7 cells (3.5-fold, P < 0.01 in one experiment, Figure 2
, and 7.0 in another experiment, not shown) as evaluated by weight of the dissected tumors. Staining of tumors with human specific antibodies revealed a histological appearance of HBFL-1 cells in the peritumoral stroma very similar to that seen with experimentally generated myofibroblasts (Figure 2)
. Double staining with human specific vimentin and
-sm actin revealed that the inoculated HBFL-1 cells and experimentally generated myofibroblasts resembled typical myofibroblasts also in vivo (Figure 2)
. It is concluded that tumor-derived myofibroblasts facilitate epithelial tumor growth in vivo.
|
That HBFL-1 cells were in fact from a neoplastic origin, and were thus derived by EMT, was suggested by the following observations.
The cells were spontaneously immortal as evidenced by the presence of telomerase activity (Figure 3A)
41
and viability for more than 3 years (70+ passages) in culture. Also, the karyotype was highly aneuploid with a modal value of 87 already in passage 9 (not shown; earlier passages not done). Moreover, in the carcinoma of origin we found a frequent and intimate association of regular nests of epithelial cancer cells with elongated fibroblastoid cells which stained for keratins with CAM 5.2 (Figure 3B)
. All fibroblastoid cells stained for vimentin and some stained for
-sm actin (not shown). Normal stroma in the periphery of the cancer biopsy was completely keratin-negative (not shown). The epithelial stromal relationship was further substantiated by the fact that HBFL-1 and laser pressure catapulted carcinoma cells from the tissue of origin were clonal with an identical non-random X-chromosome inactivation pattern (ratio less than 0.5)30,31
as assessed with the HUMARA clonality assay (Figure 3C)
. A rudimentary epithelial phenotype was revealed in the majority of cells also by double staining with antibodies against keratins and
-sm actin (Figure 4a)
. Identical data were obtained in clonal cultures (not shown). Two-dimensional gel electrophoresis of cytoskeletal extracts confirmed a weak expression of simple keratins (Figure 4b)
which was not seen in normal fibroblasts (not shown). To show a broader evidence that a combined induction of
-sm actin and loss of keratin could arise as a consequence of an EMT phenomenon was demonstrated by use of two additional basaloid breast carcinoma cell lines (HMT-3909S1 and HMT-3522T4). Under standard culture conditions these cell lines were vimentin- and keratin-positive and entirely
-sm actin-negative (not shown). In the presence of serum (HMT-3522T4)- or TGF-ß (HMT3909S1) cells, they down-regulated keratin and induced
-sm actin (Figure 4, c and d)
. Luminal epithelial MCF-7 cells failed to respond to both serum and TGF-ß treatments (not shown). To exclude the possibility that the keratin expression was an artifact of immortalization induced in culture, we compared HBFL-1 cells with two breast fibroblast cell lines we established from primary breast fibroblasts after infection with a retroviral construct containing either E6/E7 or hTERT. While these cells had extended life spans, neither expressed keratins (not shown).
|
|
|
| Discussion |
|---|
|
|
|---|
A major conclusion from our study is that EMT-derived mesenchymal cells may differentiate into nonmalignant myofibroblast-like cells. Transdifferentiation or metaplasia is seen both in human breast cancer and in rodent mammary tumors. In breast tumors the most frequent transdifferentiation takes place within the epithelial lineages leading to squamous metaplasia.44
However, in mixed mesenchymal breast tumors, reports on unequivocal mesenchymal lineages are numerous including chondroid and osteogenic differentiation.45,46
That it really represents metaplasia (the divergent hypothesis) instead of a multiclonal tumor (the convergent hypothesis) has become increasingly clear based on the numerous studies of genetic markers in microdissected cells from within different compartments of the tissue.46,47
The criteria in the present study used to categorize the cells as myofibroblastic were a fibroblastoid morphology, expression of the mesenchymal markers Thy-1 and vimentin, and most importantly the concomitant loss of keratins in some of the cells expressing
-sm actin. It is important though to emphasize that acquisition of
-sm actin in itself should not be classified as EMT. This is a frequent phenomenon in normal resident fibroblasts and only reflects an activation of the cells.43
Thus, the myofibroblast-like definition depends on complete loss of keratins and would apply only to some of the cells.22
It is, however, remarkable that the cells also respond like myofibroblasts to cytokines and sort out in the stroma like myofibroblasts inside collagen gels and in vivo. These criteria for myofibroblasts differentiation of EMT-derived cells are similar to other reports on EMT of kidney epithelial cells.48,49
It could be questioned why the HBFL-1 are not classified as myoepithelial cells since Thy-1, vimentin, and
-sm actin are also markers for myoepithelial cells in vivo.13,50-52
Indeed, the mesenchymal compartment of metaplastic carcinomas has been firmly believed to reflect myoepithelial differentiation primarily based on the expression of S-100.53
However, since keratin expression is also a hallmark of myoepithelial cells and given the criteria listed above for the definition of myofibroblasts, we found it reasonable to categorize at least those cells completely lacking keratin expression as myofibroblasts. It is possible to postulate that those cells in HBFL-1 cultures that express keratins represent the myoepithelial lineage, a possibility raised in reports on the evolution of rat mammary mixed mesenchymal tumors.54
It should however be pointed out that the cells are not expressing the myoepithelial keratin K14. It has often been stated that oncogenesis mirrors ontogenesis.55
Thus it is intriguing that in the closely related sweat gland, normal myoepithelial cells down-regulate keratin 14 by cultivation on irradiated fibroblasts.56
It is also worthwhile to recall that in mouse mammary gland, the basal cells on the tip of the developing gland ie, the cap cells, were reported to lack keratin expression.57
Thus, the loss of keratins in EMT in breast cancer to acquire a myofibroblastic phenotype may in fact recapitulate a developmental state.
Since cap cells have also been assumed to represent progenitor cells in the mouse mammary gland, another explanation for the observed EMT in mixed mesenchymal tumors would be that the origin of those tumors is an epithelial stem cell.6 This hypothesis has been used to describe the mixed phenotype of another related tumor type namely the lung carcinosarcomas.58 The large group of EMT-derived breast cancers with primarily basaloid phenotype has also been referred to as bimodal.59 HBFL-1 cells do not generate bona fide luminal epithelial cells or myoepithelial cells and as such should not be classified as stem or progenitor cells. However, in analogy with lung carcinosarcomas, they may well be downstream of an ancestral progenitor cell.
A most surprising final conclusion of our functional studies of HBFL-1 is that they are not intrinsically tumorigenic. Therefore, it is worthwhile to incorporate into the list of consequences of EMT, the indirect action of nonmalignant EMT-derived cells on associated tumor cells as a mechanism of facilitating tumor growth. The current paradigm would appear then to be that some EMT-derived cells encourage their neighbors to be more malignant rather than performing themselves.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by The Icelandic Research Fund for Graduate Students, Dansk Kræftforskningsfond, The Dagmar Marshallsfond (to T.G.), The Danish Research Council, The Novo Nordisk Foundation, The Thaysen Foundation, Friis Fonden, The Meyer Foundation, The Danish Cancer Society, The Danish Research Council, The Danish Medical Association Research Fund (to O.W.P. and L.R.-J.), Weimanns Legat (to L.R.-J.) and The US National Cancer Institute (grant CA-64786-02 to M.J.B. and O.W.P.) and United States Department of Energy Office of Biological and Environmental Research (contract DE-AC03-76SF00098 to M.J.B.).
Accepted for publication October 14, 2002.
| References |
|---|
|
|
|---|
-smooth muscle actin by transforming growth factor-ß1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia Lab Invest 1993, 68:696-707[Medline]
This article has been cited by other articles:
![]() |
V. Gioni, T. Karampinas, G. Voutsinas, A. E. Roussidis, S. Papadopoulos, N. K. Karamanos, and D. Kletsas Imatinib Mesylate Inhibits Proliferation and Exerts an Antifibrotic Effect in Human Breast Stroma Fibroblasts Mol. Cancer Res., May 1, 2008; 6(5): 706 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Radisky and J. A. Przybylo Matrix Metalloproteinase-induced Fibrosis and Malignancy in Breast and Lung Proceedings of the ATS, April 15, 2008; 5(3): 316 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Satoh, S. Hamada, K. Kimura, A. Kanno, M. Hirota, J. Umino, W. Fujibuchi, A. Masamune, N. Tanaka, K. Miura, et al. Up-Regulation of MSX2 Enhances the Malignant Phenotype and Is Associated with Twist 1 Expression in Human Pancreatic Cancer Cells Am. J. Pathol., April 1, 2008; 172(4): 926 - 939. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Andarawewa, A. C. Erickson, W. S. Chou, S. V. Costes, P. Gascard, J. D. Mott, M. J. Bissell, and M. H. Barcellos-Hoff Ionizing Radiation Predisposes Nonmalignant Human Mammary Epithelial Cells to Undergo Transforming Growth Factor {beta} Induced Epithelial to Mesenchymal Transition Cancer Res., September 15, 2007; 67(18): 8662 - 8670. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P.V. Shekhar, S. Santner, K. A. Carolin, and L. Tait Direct Involvement of Breast Tumor Fibroblasts in the Modulation of Tamoxifen Sensitivity Am. J. Pathol., May 1, 2007; 170(5): 1546 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Koyama, T. Hibi, Z. Isogai, M. Yoneda, M. Fujimori, J. Amano, M. Kawakubo, R. Kannagi, K. Kimata, S. Taniguchi, et al. Hyperproduction of Hyaluronan in Neu-Induced Mammary Tumor Accelerates Angiogenesis through Stromal Cell Recruitment: Possible Involvement of Versican/PG-M Am. J. Pathol., March 1, 2007; 170(3): 1086 - 1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takkunen, R. Grenman, M. Hukkanen, M. Korhonen, A. Garcia de Herreros, and I. Virtanen Snail-dependent and -independent Epithelial-Mesenchymal Transition in Oral Squamous Carcinoma Cells J. Histochem. Cytochem., November 1, 2006; 54(11): 1263 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, H. Chen, B. Parker, E. Rubin, T. Zhu, J. S. Lee, P. Argani, and S. Sukumar HOXB7, a Homeodomain Protein, Is Overexpressed in Breast Cancer and Confers Epithelial-Mesenchymal Transition Cancer Res., October 1, 2006; 66(19): 9527 - 9534. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hanson, J. W. Gillespie, A. Grover, M. A. Tangrea, R. F. Chuaqui, M. R. Emmert-Buck, J. A. Tangrea, S. K. Libutti, W. M. Linehan, and K. G. Woodson Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst, February 15, 2006; 98(4): 255 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Simian, A. Molinolo, and C. Lanari Involvement of Matrix Metalloproteinase Activity in Hormone-Induced Mammary Tumor Regression Am. J. Pathol., January 1, 2006; 168(1): 270 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Cardiff Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace? Clin. Cancer Res., December 15, 2005; 11(24): 8534 - 8537. [Full Text] [PDF] |
||||
![]() |
C. A. Sartorius, D. M.E. Harvell, T. Shen, and K. B. Horwitz Progestins Initiate a Luminal to Myoepithelial Switch in Estrogen-Dependent Human Breast Tumors without Altering Growth Cancer Res., November 1, 2005; 65(21): 9779 - 9788. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Galie, C. Sorrentino, M. Montani, L. Micossi, E. Di Carlo, T. D'Antuono, L. Calderan, P. Marzola, D. Benati, F. Merigo, et al. Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells Carcinogenesis, November 1, 2005; 26(11): 1868 - 1878. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Radisky Epithelial-mesenchymal transition J. Cell Sci., October 1, 2005; 118(19): 4325 - 4326. [Full Text] [PDF] |
||||
![]() |
C. H. Stuelten, S. D. Byfield, P. R. Arany, T. S. Karpova, W. G. Stetler-Stevenson, and A. B. Roberts Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-{alpha} and TGF-{beta} J. Cell Sci., May 15, 2005; 118(10): 2143 - 2153. [Abstract] [Full Text] [PDF] |
||||
| ||||||